Literature DB >> 15808321

In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

Samuel K Bouchillon1, Daryl J Hoban, Brian M Johnson, Tim M Stevens, Michael J Dowzicky, David H Wu, Patricia A Bradford.   

Abstract

Tigecycline is the first glycylcycline antimicrobial in phase III clinical trials. This study compares the in vitro activity of tigecycline to 12 other predominately broad-spectrum antimicrobials against 3049 recent inpatient isolates from 38 clinical centers in 17 countries. The minimum concentration at which tigecycline inhibited 90% of the isolates for the entire collection, excluding Pseudomonas aeruginosa, was 1 microg/mL, including vancomycin-resistant enterococci-, extended-spectrum beta-lactamase-, and methicillin-resistant Staphylococcus aureus-resistant phenotypes.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15808321     DOI： 10.1016/j.diagmicrobio.2004.11.006

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  14 in total

1.  In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Authors:  Maria Souli; Flora V Kontopidou; Evangelos Koratzanis; Anastasia Antoniadou; Efthimia Giannitsioti; Pinelopi Evangelopoulou; Sofia Kannavaki; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.

Authors:  María-Isabel Morosini; María García-Castillo; Teresa M Coque; Aránzazu Valverde; Angela Novais; Elena Loza; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

6.  Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.

Authors:  Toyotaka Sato; Yuuki Suzuki; Tsukasa Shiraishi; Hiroyuki Honda; Masaaki Shinagawa; Soh Yamamoto; Noriko Ogasawara; Hiroki Takahashi; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

7.  In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.

Authors:  Visanu Thamlikitkul; Suwanna Trakulsomboon
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii.

Authors:  Marc H Scheetz; Chao Qi; John R Warren; Michael J Postelnick; Teresa Zembower; Arlene Obias; Gary A Noskin
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

9.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

10.  High abundance and diversity of antimicrobial resistance determinants among early vancomycin-resistant Enterococcus faecium in Poland.

Authors:  E Sadowy; A Sieńko; I Gawryszewska; A Bojarska; K Malinowska; W Hryniewicz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-04-05       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.